Keep Me Logged In
John Eade, Argus Research, discusses Pfizer's likely next move after abandoning its attempt to buy AstraZeneca. There's a good chance AstraZeneca management could ask Pfizer to come back to the table, says Eade.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by